Prostate Cancer
Discovery of BWA-522, a First-in-Class and Orally Bioavailable PROTAC Degrader of the Androgen Receptor Targeting N-Terminal Domain for the Treatment of Prostate Cancer.
September 14, 2023
Fulvestrant increases the susceptibility of enzalutamide-resistant prostate cancer cells to NK-mediated lysis.
September 14, 2023
Evolution of structural rearrangements in prostate cancer intracranial metastases.
September 14, 2023
BOP Preliminary Trial Results Presented at EANM 2023 Conference
September 13, 2023
Evaluation of Industry Payments to US Advanced Practice Clinicians in 2021
September 13, 2023
Racial and ethnic differences in perceptions of germline or somatic DNA sequencing among patients with advanced prostate, urothelial, or kidney cancer.
September 13, 2023
Limitations of Prostate Biopsy in Detection of Cribriform and Intraductal Prostate Cancer.
September 13, 2023
Treatment patterns and outcomes in older adults with castration-resistant prostate cancer: Analysis of an Australian real-world cohort.
September 13, 2023
Mount Sinai Awarded $3.4 Million to Study Prostate Cancer in People With HIV
September 12, 2023
Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines.
September 12, 2023
Clinical Germline Testing Results of Men With Prostate Cancer: Patient-Level Factors and Implications of NCCN Guideline Expansion.
September 12, 2023
Germline Genetic Testing After Cancer Diagnosis.
September 12, 2023
Real-world genetic testing patterns in metastatic castration-resistant prostate cancer.
September 12, 2023
Prognostic Role of Dynamic Changes in Serological Markers in Metastatic Hormone Naïve Prostate Cancer.
September 12, 2023